GlassScriptPhysician profile
Robert Joseph Healy
NPI 1164400123
$23,820.35
in general payments reported to CMS, 2019-2025
66 companies · $3,388 in 2025
The $3,388 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,923 · 2020: $3,022 · 2021: $3,313 · 2022: $3,408 · 2023: $3,749 · 2024: $4,017 · 2025: $3,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $10.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,143.00 |
| Education | $10.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,163.96 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,777.13 | 2019-2025 | |
| Biogen, INC. | $1,451.47 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Genzyme Corporation | $1,348.28 | 2019-2025 | |
| Emd Serono, INC. | $1,141.74 | 2019-2025 | Mavenclad |
| Acadia Pharmaceuticals INC | $1,035.94 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $941.75 | 2019-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $919.23 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $727.77 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $678.02 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $643.12 | 2019-2025 | Qelbree |
| Mdd US Operations, LLC | $635.39 | 2019-2025 | Gocovri, Gocovri, Xadago |
| Pfizer INC. | $563.00 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $543.82 | 2020-2025 | Acthar |
| Neurocrine Biosciences, INC. | $535.93 | 2020-2025 | Ingrezza, Ongentys |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Healy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.